RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy | MicrobiomeTrials
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2023-12-20Est. Completion: 2028-07
Enrollment target: 74 participants
Locations
University of California Irvine - Accepting Adult Patients, Orange, California, United States
University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients, San Francisco, California, United States
Children's Hospital Colorado - Accepting Juvenile Patients, Aurora, Colorado, United States
Mayo Clinic Florida - Accepting Adult Patients, Jacksonville, Florida, United States
Johns Hopkins All Children's Hospital - Accepting Juvenile Patients, St. Petersburg, Florida, United States
Children's Healthcare of Atlanta - Accepting Juvenile Patients, Atlanta, Georgia, United States
Emory University - Accepting Adult Patients, Atlanta, Georgia, United States
Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients, Chicago, Illinois, United States
Northwestern Memorial Hospital - Accepting Adult Patients, Chicago, Illinois, United States
The University of Chicago Medical Center - Accepting Adult and Juvenile Patients, Chicago, Illinois, United States
University of Kansas Medical Center - Accepting Adult Patients, Kansas City, Kansas, United States
National Institutes of Health - Accepting Adult and Juvenile Patients, Bethesda, Maryland, United States
Other microbiome trials you might be interested in